Increased expression of mRNA specific for c-Met oncogene in human papillary thyroid carcinoma

Archives of Medical Science

Volumn 3, Issue 1, 2007, Pages 31-36

  Cyniak Magierska, Anna ^a   Brzeziańska, Ewa ^a   Januszkiewicz Caulier, Joanna ^a   Pastuszak Lewandoska, Dorota ^a   Lewiński, Andrzej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Human papillary thyroid carcinoma; mRNA expression; Oncogene c Met

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; SCATTER FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; POLAND; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; THYROID CARCINOMA;

EID: 34247336439     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Sherman S. Thyroid carcinoma. Lancet 2003; 361: 501-11.
2. Lewiński A, Ferenc T, Sporny S, Jarza̧b B. Thyroid carcinoma: diagnostic and therapeutic approach; genetic background. Endocr Regul 2000; 34: 99-113.
3. Brzeziańska E, Karbownik M, Migdalska-Sȩk M, Pastuszak-Lewandoska D, Włoch J, Lewiński A. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. Mutat Res 2006; 599: 26-35.
4. Musholt TJ, Musholt PB, Khaladj N, Schulz D, Scheumann GF, Klempnauer J. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma. Surgery 2000; 128: 984-93.
5. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the pathogenesis of PTC. Oncogene 2003; 22: 4578-80.
6. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signalling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-7.
7. Karbownik M, Brzeziańska E, Lewinski A. Increased expression of mRNA specific for thymidine kinase, deoxycytidine kinase or thymidine phosphorylase in human papillary thyroid carcinoma. Cancer Lett 2005; 225: 267-73.
8. Giordano S, Di Renzo MF, Narsimhan RP, Cooper CS, Rosa C, Comoglio PM. Biosynthesis of the protein encoded by the c-Met proto-oncogene. Oncogene 1989; 4: 1383-8.
9. Naldini L, Vigna E, Narsimhan RP, et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-met. Oncogene 1991; 6: 501-4.
10. Scarpino S, Stoppacciaro A, Colarossi C, et al. Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroid. J Pathol 1999; 189: 570-5.
11. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002; 109: 863-7.
12. Di Renzo MF, Olivero M, Ferro S, et al. Overexpression of the c-Met/HGF receptor gene in human thyroid carcinomas. Oncogene 1992; 7: 2549-53.
13. Chen BK, Ohtsuki Y, Furihata M, et al. Overexpression of c-met protein in human thyroid tumours correlated with lymph node metastasis and clinicopathologic stage. Pathol Res Pract 1999; 195: 427-33.
14. Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H. Hepatocyte growth factor receptor, matrix metaltoproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma. Clin Cancer Res 2003; 9: 68-75.
15. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the Met proto-oncogene in papillary renal carcinoma. Nat Genet 1997; 16: 68-73.
16. Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, Nupponen NN, Franssila K, Joensuu H. MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am J Surg Pathol 2005; 29: 544-9.
17. th ed. Springer, New York 2000; pp: 89-98.
18. Trovato M, Villari D, Bartolone L, et al. Expression of the hepatocyte growth factor and c-met in normal thyroid, non neoplastic, and neoplastic nodules. Thyroid 1998; 8: 125-31.
19. Nardone HC, Ziober AF, LiVolsi VA, et al. c-Met expression in tall cell variant papillary carcinoma of the thyroid. Cancer 2003; 98: 1386-93.
20. Fluge Ø, Haugen D, Lillehaug JR, Varhaug JE. Difference in patterns of Met expression in papillary thyroid carcinomas and nonneoplastic thyroid tissue. World J Surg 2001; 25: 623-31.
21. Jarza̧b B, Wiench M, Fujarewicz K, et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 2005; 65: 1587-97.
22. Ivan M, Bond JA, Prat M, Comoglio PM, Wynford-Thomas D. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 1997; 14: 2417-23.
23. Cyniak-Magierska A, Brzeziańska E, Pastuszak-Lewandoska D, Januszkiewicz J, Lewiński A. Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS. Endokrynol Pol 2004; 55: 98-99.
24. Brzeziańska E, Pastuszak-Lewandoska D, Migdalska-Sȩk D, Wojciechowska K, Lewiński A. Incidence assessment of BRAF V599E mutation in papillary thyroid carcinoma in the polish population. Endokrynol Pol 2005; 56: 561-62.
25. Fukushima T, Suzuki S, Mashico M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003; 22: 6455-7.
26. Schulte KM, Antoch G, Ellrichmann M, et al. Regulation of the HGF-receptor c-Met in the thyroid gland. Exp Clin Endocrinol Diabetes 1998; 106: 310-8.